ADAM12 alleviates the skeletal muscle pathology in mdx dystrophic mice

American Journal of Pathology

Volumn 161, Issue 5, 2002, Pages 1535-1540

  Kronqvist, Pauliina ^a   Kawaguchi, Nobuko ^a   Albrechtsen, Reidar ^a   Xu, Xiufeng ^a   Daa Schrøder, Henrik ^b   Moghadaszadeh, Behzad ^a   Cilius Nielsen, Finn ^a   Fröhlich, Camilla ^a   Engvall, Eva ^c   Wewer, Ulla M ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; DISINTEGRIN; DYSTROPHIN; EVANS BLUE; METALLOPROTEINASE; METALLOPROTEINASE ADAM 12; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DYSTROPHY; FEMALE; KNOCKOUT MOUSE; MOLECULAR STABILITY; MOUSE; MUSCLE CELL; MUSCLE NECROSIS; MUSCLE REGENERATION; MYOSITIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; SKELETAL MUSCLE;

EID: 0036841772     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64431-8     Document Type: Article

References (40)

1. Cohn RD, Campbell KP: Molecular basis of muscular dystrophies. Muscle Nerve 2000, 23:1456-1471
2. O'Brien KF, Kunkel LM: Dystrophin and muscular dystrophy: Past, present, and future. Mol Genet Metab 2001, 74:75-88
3. Muntoni F, Guicheney P: 85th ENMC International Workshop on Congenital Muscular Dystrophy. 6th International CMD Workshop. 1st Workshop of the Myo-Cluster Project 'GENRE'. 27-28th October 2000, Naarden, The Netherlands. Neuromuscul Disord 2002, 12: 69-78
4. Burton EA, Davies KE: Muscular dystrophy - Reason for optimism? Cell 2002, 108:5-8
5. Dubowitz V: Therapeutic possibilities in muscular dystrophy: The hope versus the hype. Neuromuscul Disord 2002, 12:113-116
6. Wakefield PM, Tinsley JM, Wood MJ, Gilbert R, Karpati G, Davies KE: Prevention of the dystrophic phenotype in dystrophin/utrophin-deficient muscle following adenovirus-mediated transfer of a utrophin minigene. Gene Ther 2000. 7:201-204
7. Miller JB, Schaefer L, Dominov JA: Seeking muscle stem cells. Curr Top Dev Biol 1999, 43:191-219
8. Seale P, Asakura A, Rudnicki MA: The potential of muscle stem cells. Dev Cell 2001, 1:333-342
9. Anderson JE, Weber M, Vargas C: Deflazacort increases laminin expression and myogenic repair, and induces early persistent functional gain in mdx mouse muscular dystrophy. Cell Transplant 2000, 9:551-564
10. Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL: Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 1999, 104:375-381
11. Wehling M, Spencer MJ, Tidball JG: A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. J Cell Biol 2001, 155: 123-131
12. Nguyen HH, Jayasinha V, Xia B, Hoyte K, Martin PT: Overexpression of the cytotoxic T cell GaINAc transferase in skeletal muscle inhibits muscular dystrophy in mdx mice. Proc Natl Acad Sci USA 2002, 99:5616-5621
13. Isaka Y, Brees DK, Ikegaya K, Kaneda Y, Imai E, Noble NA, Border WA: Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med 1996, 2:418-423
14. Grounds MD: Muscle regeneration: Molecular aspects and therapeutic implications. Curr Opin Neurol 1999, 12:535-543
15. Black RA, White JM: ADAMs: Focus on the protease domain. Curr Opin Cell Biol 1998, 10:654-659
16. Werb Z, Yan Y: A cellular striptease act. Science 1998, 282:1279-1280
17. Blobel CP: Remarkable roles of proteolysis on and beyond the cell surface. Curr Opin Cell Biol 2000, 12:606-612
18. Primakoff P, Myles DG: The ADAM gene family: Surface proteins with adhesion and protease activity. Trends Genet 2000, 16:83-87
19. Yagami-Hiromasa T, Sato T, Kurisaki T, Kamijo K, Nabeshima Y, Fujisawa-Sehara A: A metalloprotease-disintegrin participating in myoblast fusion. Nature 1995, 377:652-656
20. Kurisaki T, Masuda A, Osumi N, Nabeshima Y, Fujisawa-Sehara A: Spatially- and temporally-restricted expression of meltrin alpha (ADAM12) and beta (ADAM19) in mouse embryo. Mech Dev 1998, 73:211-215
21. Galliano MF, Huet C, Frygelius J, Polgren A, Wewer UM, Engvall E: Binding of ADAM12, a marker of skeletal muscle regeneration, to the muscle-specific actin-binding protein, alpha-actinin-2, is required for myoblast fusion. J Biol Chem 2000, 275:13933-13939
22. Borneman A, Kuschel R, Fujisawa-Sehara A: Analysis for transcript expression of meltrin alpha in normal, regenerating, and denervated rat muscle. J Muscle Res Cell Motil 2000, 21:475-480
23. Gilpin BJ, Loechel F, Mattei MG, Engvall E, Albrechtsen R, Wewer UM: A novel, secreted form of human ADAM 12 (meltrin alpha) provokes myogenesis in vivo. J Biol Chem 1998, 273:157-166
24. Kawaguchi N, Xu X, Tajima R, Kronqvist P, Sundberg C, Loechel F, Albrechtsen R, Wewer UM: ADAM 12 protease induces adipogenesis in transgenic mice. Am J Pathol 2002, 160:1895-1903
25. lba K, Albrechtsen R, Gilpin BJ, Loechel F, Wewer UM: Cysteine-rich domain of human ADAM 12 (meltrin alpha) supports tumor cell adhesion. Am J Pathol 1999, 154:1489-1501
26. Iba K, Albrechtsen R, Gilpin B, Frohlich C, Loechel F, Zolkiewska A, Ishiguro K, Kojima T, Liu W, Langford JK, Sanderson RD, Brakebusch C, Fassler R, Wewer UM: The cysteine-rich domain of human ADAM 12 supports cell adhesion through syndecans and triggers signaling events that lead to beta1 integrin-dependent cell spreading. J Cell Biol 2000, 149:1143-1156
27. Loechel F, Fox JW, Murphy G, Albrechtsen R, Wewer UM: ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem Biophys Res Commun 2000, 278:511-515
28. Matsuda R, Nishikawa A, Tanaka H: Visualization of dystrophic muscle fibers in mdx mouse by vital staining with Evans blue: Evidence of apoptosis in dystrophin-deficient muscle. J Biochem (Tokyo) 1995, 118:959-964
29. Straub V, Rafael JA, Chamberlain JS, Campbell KP: Animal models for muscular dystrophy show different patterns of sarcolemmal disruption. J Cell Biol 1997, 139:375-385
30. Eto K, Puzon-McLaughlin W, Sheppard D, Sehara-Fujisawa A, Zhang XP, Takada Y: RGD-independent binding of integrin alpha9beta1 to the ADAM-12 and -15 disintegrin domains mediates cell-cell interaction. J Biol Chem 2000, 275:34922-34930
31. Zolkiewska A: Disintegrin-like/cysteine-rich region of ADAM 12 is an active cell adhesion domain. Exp Cell Res 1999, 252:423-431
32. Raab G, Klagsbrun M: Heparin-binding EGF-like growth factor. Biochim Biophys Acta 1997, 1333:F179-F199
33. Asakura M, Kitakaze M, Takashima S, Liao Y, Ihikura F, Yoshinaka T, Ohmoto H, Node K, Yoshino K, Ishiguro H, Asanuma H, Sanada S, Matsumura Y, Takeda H, Beppu S, Tada M, Hori M, Higashiyama S: Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy. Nat Med 2002, 8:35-40
34. Shi Z, Xu W, Loechel F, Wewer UM, Murphy LJ: ADAM 12, a disintegrin metalloprotease, interacts with insulin-like growth factor-binding protein-3. J Biol Chem 2000, 275:18574-18580
35. Florini JR, Ewton DZ, Coolican SA: Growth hormone and the insulin-like growth factor system in myogenesis. Endocr Rev 1996, 17:481-517
36. Barton ER, Morris L, Musaro A, Rosenthal N, Sweeney HL: Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J Cell Biol 2002, 157:137-148
37. Tinsley JM, Potter AC, Phelps SR, Fisher R, Trickett JI, Davies KE: Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene. Nature 1996, 384:349-353
38. Burkin DJ, Wallace GQ, Nicol KJ, Kaufman DJ, Kaufman SJ: Enhanced expression of the alpha 7 beta 1 integrin reduces muscular dystrophy and restores viability in dystrophic mice J Cell Biol 2001, 152:1207-1218
39. Moll J, Barzaghi P, Lin S, Bezakova G, Lochmuller H, Engvall E, Muller U, Ruegg MA: An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophy. Nature 2001, 413: 302-307
40. Kuang W, Xu H, Vachon PH, Liu L, Loechel F, Wewer UM, Engvall E: Merosin-deficient congenital muscular dystrophy. Partial genetic correction in two mouse models. J Clin Invest 1998, 102:844-852